196 related articles for article (PubMed ID: 30408079)
1. Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.
Suijkerbuijk AWM; van Hoek AJ; Koopsen J; de Man RA; Mangen MJ; de Melker HE; Polder JJ; de Wit GA; Veldhuijzen IK
PLoS One; 2018; 13(11):e0207037. PubMed ID: 30408079
[TBL] [Abstract][Full Text] [Related]
2. Screening for chronic hepatitis B and C in migrants from Afghanistan, Iran, Iraq, the former Soviet Republics, and Vietnam in the Arnhem region, The Netherlands.
Richter C; Ter Beest G; Gisolf EH; VAN Bentum P; Waegemaekers C; Swanink C; Roovers E
Epidemiol Infect; 2014 Oct; 142(10):2140-6. PubMed ID: 24398373
[TBL] [Abstract][Full Text] [Related]
3. Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective.
Veldhuijzen IK; Toy M; Hahné SJ; De Wit GA; Schalm SW; de Man RA; Richardus JH
Gastroenterology; 2010 Feb; 138(2):522-30. PubMed ID: 19879275
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of screening immigrants for hepatitis B.
Wong WW; Woo G; Jenny Heathcote E; Krahn M
Liver Int; 2011 Sep; 31(8):1179-90. PubMed ID: 21745300
[TBL] [Abstract][Full Text] [Related]
5. The Cost-Effectiveness of Hepatitis C Virus Screening Strategies among Recently Arrived Migrants in the Netherlands.
Al Khayat MNMT; Eijsink JFH; Postma MJ; Wilschut JC; van Hulst M
Int J Environ Res Public Health; 2020 Aug; 17(17):. PubMed ID: 32825680
[TBL] [Abstract][Full Text] [Related]
6. Cost Effectiveness of Early Treatment with Direct-Acting Antiviral Therapy in Adolescent Patients with Hepatitis C Virus Infection.
Nguyen J; Barritt AS; Jhaveri R
J Pediatr; 2019 Apr; 207():90-96. PubMed ID: 30738661
[TBL] [Abstract][Full Text] [Related]
7. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of hepatitis C virus screening, and subsequent monitoring or treatment among pregnant women in the Netherlands.
Eijsink JFH; Al Khayat MNMT; Boersma C; Ter Horst PGJ; Wilschut JC; Postma MJ
Eur J Health Econ; 2021 Feb; 22(1):75-88. PubMed ID: 33064259
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B screening and vaccination strategies for newly arrived adult Canadian immigrants and refugees: a cost-effectiveness analysis.
Rossi C; Schwartzman K; Oxlade O; Klein MB; Greenaway C
PLoS One; 2013; 8(10):e78548. PubMed ID: 24205255
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients.
Blázquez-Pérez A; San Miguel R; Mar J
Pharmacoeconomics; 2013 Oct; 31(10):919-31. PubMed ID: 24000086
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness and health-related outcomes of screening for hepatitis C in Korean population.
Kim KA; Chung W; Choi HY; Ki M; Jang ES; Jeong SH
Liver Int; 2019 Jan; 39(1):60-69. PubMed ID: 29998565
[TBL] [Abstract][Full Text] [Related]
12. A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: A societal perspective.
Kim HL; Kim KA; Choi GH; Jang ES; Ki M; Choi HY; Jeong SH
Clin Mol Hepatol; 2022 Jan; 28(1):91-104. PubMed ID: 34736311
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B.
Hutton DW; Tan D; So SK; Brandeau ML
Ann Intern Med; 2007 Oct; 147(7):460-9. PubMed ID: 17909207
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population.
Chahal HS; Marseille EA; Tice JA; Pearson SD; Ollendorf DA; Fox RK; Kahn JG
JAMA Intern Med; 2016 Jan; 176(1):65-73. PubMed ID: 26595724
[TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings.
Rein DB; Smith BD; Wittenborn JS; Lesesne SB; Wagner LD; Roblin DW; Patel N; Ward JW; Weinbaum CM
Ann Intern Med; 2012 Feb; 156(4):263-70. PubMed ID: 22056542
[TBL] [Abstract][Full Text] [Related]
16. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
Hartwell D; Jones J; Baxter L; Shepherd J
Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation.
Crossan C; Tsochatzis EA; Longworth L; Gurusamy K; Davidson B; Rodríguez-Perálvarez M; Mantzoukis K; O'Brien J; Thalassinos E; Papastergiou V; Burroughs A
Health Technol Assess; 2015 Jan; 19(9):1-409, v-vi. PubMed ID: 25633908
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of Universal and Targeted Hepatitis C Virus Screening in the United States.
Tatar M; Keeshin SW; Mailliard M; Wilson FA
JAMA Netw Open; 2020 Sep; 3(9):e2015756. PubMed ID: 32880650
[TBL] [Abstract][Full Text] [Related]
19. Cost Effectiveness of Universal Screening for Hepatitis C Virus Infection in the Era of Direct-Acting, Pangenotypic Treatment Regimens.
Eckman MH; Ward JW; Sherman KE
Clin Gastroenterol Hepatol; 2019 Apr; 17(5):930-939.e9. PubMed ID: 30201597
[TBL] [Abstract][Full Text] [Related]
20. [Serological and sociodemographic differences in HBV-patients with and without migration background].
Wörmann T; Prüfer-Krämer L; Krämer A
Z Gastroenterol; 2010 May; 48(5):533-41. PubMed ID: 20449785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
